ABOS Stock Analysis: Acumen Pharmaceuticals | NASDAQ

Alzheimers Drug, Immunotherapy

Total Rating 22

Safety 43

Buy Signal -0.37

Biotechnology
Industry Rotation: -12.7

Market Cap: 143M
Avg Turnover: 1.18M

Risk 3d forecast

Volatility84.1%

VaR 5^th Pctl14.0%

VaR vs Median0.76%

Reward TTM

Sharpe Ratio0.38

Rel. Str. IBD46.3

Rel. Str. Peer Group46.5 pctl

Character TTM

Beta1.639

Beta Downside1.578

Hurst Exponent0.526

Choppyness55.4%

Drawdowns 3y

Max DD80.58%

CAGR/Max DD0.01

CAGR/Mean DD0.02

EPS (Earnings per Share)

Last SUE: 0.46
Qual. Beats: 0

Revenue

Last SUE: 0.00
Qual. Beats: 0

Warnings

Strong Share Dilution

Interest Coverage Ratio Critical

Altman Z'' In Financial Distress Zone

Below Sma 200d

Tailwinds

Ep Pivot

Seasonality

Not enough history

Description: ABOS Acumen Pharmaceuticals

Acumen Pharmaceuticals, Inc. (ABOS) is a clinical-stage biopharmaceutical company developing treatments for Alzheimers disease. The companys primary focus is Sabirnetug (ACU193), an immunotherapy drug targeting soluble amyloid-beta oligomers.

Sabirnetug has completed Phase 1 and is currently in Phase 2 clinical trials. The biotechnology sector frequently involves lengthy and costly research and development phases, with high risk and potential for significant returns upon successful drug approval. ABOS also has a collaboration with Halozyme, Inc. to develop a subcutaneous formulation of Sabirnetug, indicating a potential strategy to enhance drug delivery and patient convenience.

Further research on ValueRay can provide detailed insights into ABOSs financial performance and pipeline progress.

Headlines to Watch Out For

Sabirnetug (ACU193) clinical trial results significantly impact stock valuation
Regulatory approval of Alzheimers drug crucial for commercialization
Competition in Alzheimers drug development affects market share
Collaboration with Halozyme expands drug delivery options

Piotroski VR-10 (Strict) 0.5

Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.79 > 0.02 and ΔFCF/TA -10.56 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.79 > 3% & CFO -91.8m > Net Income -105.0m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 2.47 > 1.5 & < 3
Outstanding Shares: last quarter (72.3m) vs 12m ago 19.28% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.10%; Δ -0.10% > 0%)
Interest Coverage Ratio: -23.33 > 6 (EBIT TTM -100.7m / Interest Expense TTM 4.32m)

Altman Z'' -13.84

A: 0.59 (Total Current Assets 115.5m - Total Current Liabilities 46.8m) / Total Assets 116.0m
B: -4.31 (Retained Earnings -499.9m / Total Assets 116.0m)
C: -0.70 (EBIT TTM -100.7m / Avg Total Assets 144.0m)
D: 0.97 (Book Value of Equity 57.3m / Total Liabilities 58.7m)
Altman-Z'' = -13.84 = D

What is the price of ABOS shares?

As of October 27, 2026, the stock is trading at USD 2.27 with a total of 1,645,535 shares traded. Over the past week, the price has changed by +28.25%, over one month by -1.30%, over three months by +3.18% and over the past year by +3.18%.

Current recommended Stop Loss: 1.90 (which is 16.3% or 2.3 ATR below the current price).

Is ABOS a buy, sell or hold?

Acumen Pharmaceuticals has received a consensus analysts rating of 5.00. Therefore, it is recommended to buy ABOS.

StrongBuy: 6
Buy: 0
Hold: 0
Sell: 0
StrongSell: 0

What are the forecasts/targets for the ABOS price?

Analysts Target Price	7.6	234.8%

Acumen Pharmaceuticals (ABOS) - Fundamental Data Overview as of 27 October 2026

Market Cap USD = 143.2m (143.2m USD * 1.0 USD.USD)
P/S = 538.7842
P/B = 3.2835
Revenue TTM = 0.0 USD
EBIT TTM = -100.7m USD
EBITDA TTM = -100.5m USD
Long Term Debt = 11.9m USD (from longTermDebt, last quarter)
Short Term Debt = 19.8m USD (from shortTermDebt, last quarter)
Debt = 31.6m USD (from shortLongTermDebtTotal, last quarter) + Leases 77.0k
Net Debt = -78.6m USD (calculated: Debt 31.6m - CCE 110.2m)
Enterprise Value = 64.6m USD (143.2m + Debt 31.6m - CCE 110.2m)
Interest Coverage Ratio = -23.33 (Ebit TTM -100.7m / Interest Expense TTM 4.32m)
EV/FCF = -0.70x (Enterprise Value 64.6m / FCF TTM -91.8m)
FCF Yield = -142.0% (FCF TTM -91.8m / Enterprise Value 64.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 184k) / Revenue TTM)
Tobins Q-Ratio = 0.56 (Enterprise Value 64.6m / Total Assets 116.0m)
Interest Expense / Debt = 13.64% (Interest Expense 4.32m / Debt 31.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -79.6m (EBIT -100.7m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 2.47 (Total Current Assets 115.5m / Total Current Liabilities 46.8m)
Debt / Equity = 0.55 (Debt 31.6m / totalStockholderEquity, last quarter 57.3m)
Debt / EBITDA = 0.78 (negative EBITDA) (Net Debt -78.6m / EBITDA -100.5m)
Debt / FCF = 0.86 (negative FCF - burning cash) (Net Debt -78.6m / FCF TTM -91.8m)
Total Stockholder Equity = 77.1m (last 4 quarters mean from totalStockholderEquity)
RoA = -72.97% (Net Income -105.0m / Total Assets 116.0m)
RoE = -136.3% (Net Income TTM -105.0m / Total Stockholder Equity 77.1m)
RoCE = -113.2% (out of range, set to none) (EBIT -100.7m / Capital Employed (Equity 77.1m + L.T.Debt 11.9m))
RoIC = -89.50% (negative operating profit) (NOPAT -79.6m / Invested Capital 88.9m)
WACC = 11.07% (E(143.2m)/V(174.8m) * Re(11.14%) + D(31.6m)/V(174.8m) * Rd(13.64%) * (1-Tc(0.21)))
Discount Rate = 11.14% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 66.54 | Cagr: 8.76%
[DCF] Fair Price = unknown (Cash Flow -91.8m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.46 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Year (2026-12-31): EPS=-1.62 | Chg30d=-1.97% | Revisions=-17% | GrowthEPS=+19.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-1.43 | Chg30d=-0.07% | Revisions=+17% | GrowthEPS=+11.5% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +0% (up=3, down=3)